Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | Biomarkers for precision medicine in hormone-sensitive prostate cancer

Umang Swami • 13 Feb 2025
GU Cancers 2025
Genitourinary Cancer Prostate Cancer
CAPItello-281

Umang Swami, MD, MS, University of Utah, Salt Lake City, UT, discusses emerging biomarkers for targeted therapies in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Both low PSA levels (recorded 0.2 ng/mL) and SPOP+ patients treated with androgen receptor pathway inhibitors (ARPIs) are markers of good prognosis, whereas TP53 and RB1 are reported as markers of poor prognosis in patients with mHSPC. Dr Swami also discusses the potential approval of a new treatment with PTEN alterations in patients following successes in the CAPItello-281 trial (NCT04493853). This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Umang Swami

OPTIMAS:a de-escalation trial in mHSPC achieving optimal PSA response
3:03
OPTIMAS:a de-escalation trial in mHSPC achieving optimal PSA response
Umang Swami • 27 Feb 2026
De-escalation strategies to reduce ADT and ARPI burden in prostate cancer
1:07
De-escalation strategies to reduce ADT and ARPI burden in prostate cancer
Umang Swami • 27 Feb 2026
Treating patients with prostate cancer who progress on 177Lu-PSMA-617
0:37
Treating patients with prostate cancer who progress on 177Lu-PSMA-617
Umang Swami • 13 Feb 2025
Real-world trends in ADT intensification for mHSPC in the US
1:03
Real-world trends in ADT intensification for mHSPC in the US
Umang Swami • 13 Feb 2025

Related Videos

Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
3:36
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
Tian Zhang • 1 Jun 2026
Drug repurposing and trial challenges in rare renal medullary carcinoma
3:11
Drug repurposing and trial challenges in rare renal medullary carcinoma
Pavlos Msaouel • 30 May 2026
The content of VJOncology is intended for healthcare professionals